PubMed Health⌕ Search

PubMed · 12022079

[Evoked potentials and their application in epilepsy].

Abstract

INTRODUCTION: Evoked potentials (PE) are used in a technique for functional exploration of the central nervous system which allows a response to be generated following repeated sensory stimulation. There are different modalities according to the stimulus used. The most frequently used are visual, auditory and somestesic stimuli. There are also cognitive endogenous potentials. Each response requires the use of specific methods to obtain it. DEVELOPMENT: In this paper we present a summary of the methodology for obtaining evoked potentials and also a review of their application in the field of epilepsy. There are different findings in studies using PE which are characteristic of certain syndromes in which epileptic seizures occur. Correlation of alterations in PE with the clinical findings may be of help in studying the physiopathology of epilepsy and subsequent follow up, especially for the study of cognitive functions.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Descals-Moll, J Burcet-Dardé. [Evoked potentials and their application in epilepsy].. https://pubmed.ncbi.nlm.nih.gov/12022079/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Long-term seizure outcomes and factors associated with response to adjunctive everolimus in TSC-associated epilepsy.

BACKGROUND: Everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, is increasingly used in tuberous sclerosis complex (TSC)-associated epilepsy; however, long-term real-world outcomes and factors associated with favorable response remain unclear. This study aimed to evaluate the long-term seizure outcomes of adjunctive everolimus and explore clinical factors associated with treatment response. METHODS: We retrospectively recruited 21 patients with active TSC-associated epilepsy receiving adjunctive everolimus and assessed seizure outcomes during follow-up. Clinical characteristics were compared between responders and non-responders at 1 year after treatment initiation. RESULTS: Over a median treatment duration of 72 months, responder rates ranged from 53.8% to 64.7%, and seizure-free rates ranged from 33.3% to 41.2%. Responders had fewer involved organ systems at baseline (median 3 vs. 4, p = 0.020) and lower anti-seizure medication burden (median 2 vs. 4, p = 0.045). Younger age at treatment initiation showed a trend toward improved response. CONCLUSION: Adjunctive everolimus was associated with sustained long-term seizure reduction in this real-world cohort. In exploratory analyses, fewer involved organ systems and fewer baseline ASMs were associated with favorable treatment response. These findings require validation in larger prospective cohorts.

Epilepsy↗